In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Pfizer, Allergan to combine in $160bn deal; merger scrapped due to tax law change

Executive Summary

In the largest merger in the health care industry to date, Pfizer Inc. will pay a whopping $160bn in stock--$363.63 per share (a 20% premium)--for Allergan PLC. Allergan shareholders will receive 11.3 shares in the combined entity for each of their shares. Pfizer stockholders can also choose to receive some cash instead of stock of the combined company, provided the total cash is between $6-12bn (if it's more or less than the two limits, the stock and cash elections will be prorated).

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer
    • Specialty Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Transdermal
Deal Status
  • Withdrawn
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash for Equity
    • Payment Includes Stock
    • Reverse Acquisition

Related Companies